Blog

Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research

Apr 8 • 3 min read

Missouri’s legislative body, the House of Representatives, has recently endorsed a budget legislation earmarking $10 million of the state’s opioid settlement proceeds for research grants. However, these aren’t ordinary grants. Their purpose is to delve into the potential of psilocybin as a remedy for opioid use disorder, an issue that’s currently casting a shadow over…

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Apr 5 • 3 min read

VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment. Clairvoyant believes it may achieve this milestone in H2…

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

Apr 5 • 3 min read

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, in another Australian first, its joint venture, Cortexa Pty. Ltd. (“Cortexa”),…

Filament Health Nets $2.1M in Revenue in 2023

Apr 4 • 3 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) has recently shared its financial achievements for both the final quarter and the entire fiscal year ending December 31, 2023. This period has been notable for the biotech firm specializing in the development of natural psychedelic drugs, as it reported promising increases in revenue and a…

FSD Pharma Cuts Annual Losses to $18Million; Will Need More Capital to Develop

Apr 4 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE)(CSE: HUGE) recently disclosed its audited financial results for the fourth quarter and the entirety of the fiscal year ending December 31, 2023. Currently, the company has not generated any revenue. For the year 2023, FSD Pharma reported a net loss of $18.2 million, which is an improvement from the previous…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560